Clinical Trials Browser

INDUSTRY × Adenocarcinoma × Radiosurgery × Clear all

NCT04644770 2026-03-13

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Phase 1 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms